Jack Aiello | CureTalks
Jack Aiello of San Jose, California is a leading patient advocate in multiple myeloma. In January of 1995 Jack had a terrible backache. He was diagnosed with multiple myeloma through a blood test. Since that time Jack has had stem cell transplants and clinical trials that have brought him to remission, even if only for a short time. However, ultimately he had a full allogenic (donor stem cells) transplant, resulting in a long-term remission. While he has long-term side effects, Jack's spirit remains high and is very much involved with cancer advocacy organizations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society (LLS) and Myeloma Crowd, all of which provide research dollars and education programs for multiple myeloma. He also served on myeloma committees which focus on developing clinical trials, offering his patient perspective to the National Cancer Institute, SWOG Cancer Research Institute, BMT Clinical Trials Network, and Stanford’s Scientific Review Committee.
Related Talks
Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying…
The MMRF Precision Medicine Model – How Close to Multiple Myeloma Cure Are We?
The MMRF has built a unique model that provides the only end-to-end solution in cancer research. This model is based on three interrelated…
Nonsecretory Multiple Myeloma: New Options in Assessment and Treatment
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention.…
Myeloma: 2016 Year in Review and Outlook for 2017
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose…
Post-Transplant Outcomes in High Risk Multiple Myeloma
Treatment of patients with myeloma has changed dramatically in the past years due to development of new agents and myeloma specific targets. Despite…